Assignment of Trademark. ROCHE shall assign to SYNTA ROCHE’s and its Affiliates’ entire right, title and interest in, to and under any trademark used by ROCHE, its Affiliates or Sublicensees exclusively in connection with the Commercialization of a Licensed Product, it being understood that such assignment shall not include the ROCHE name or trademark for the ROCHE company itself.
Assignment of Trademark. Calithera agrees to and hereby assigns to HPP of all of Calithera’s right, title and interest in any trademark used solely in connection with the Licensed Products, provided that said assignment shall not include any trademark relating to the name ‘Calithera’ or the business names or trade names of any of Calithera’s Affiliates or Sublicensees (“House Marks”).
Assignment of Trademark. MKG shall take all action reasonably necessary to assign all of its right, title and interest in any trademark which MKG shall have marketed or sold the Licensed Products, together with the goodwill associated therewith, to Metasyn; provided, however, that Metasyn shall thereafter identify to any Third Parties Metasyn as the supplier of any Licensed Products;
Assignment of Trademark. Quantum shall deliver to Agent, on or prior to the date that is 120 days following the Closing Date (or such later date as Agent shall agree), evidence of the filing with the United States Patent and Trademark Office of trademark maintenance documents sufficient to establish the ownership of Borrowing Agent (or another Loan Party) of those certain trademarks with registration numbers 3524111, 3524132, 3524133, 4227061, and 4432980.
Assignment of Trademark. This Agreement, and Polymation's obligations hereunder, is contingent upon Distributor assigning all of its rights to the Medtainer trademark application now pending under U.S.P.T.O. Serial Number 85822319 to Polymation, and duly filing a proper Trademark Assignment Agreement with the U.S.P.T.O. by August 13, 2013. If Distributor fails to file the assignment by August 13, 2013, this Agreement, and all rights herein, shall be automatically revoked and void. WITNESSED, ACKNOWLEDGED AND AGREED: DISTRIBUTOR: D&C Distributors, LLC /s/ Xxxx Xxxxxxxxxxx Date: 08/13/13 Xxxx Xxxxxxxxxxx, Manager /s/ Xxxxxxx Xxxxxxxx Date: 08/13/13 Xxxxxxx Xxxxxxxx, Manager POLYMATION LLC: /s/ Xxxx Xxxxxxxx Date: 08/13/13
Assignment of Trademark. Within five (5) business days after the Effective Date, Strakan shall file a statement of use with the United States Patent and Trademark Office (the “USPTO”), along with a declaration, proof of use, the required fees, and any other documents required by the USPTO in connection with such filing. Upon filing the statement of use, Strakan will execute an assignment of the Trademark and any related domain names, in substantially the same form as shown in Exhibit G (“Assignment”), transferring, as of the Effective Date, all right title and interest in and to the Trademark and the domain names which contain the Trademark, listed in Exhibit G throughout the world, to Aptalis. Strakan will cooperate with Aptalis in filing all documents required by the USPTO, any domain name registrar and any other entity to effectuate the assignment of the Trademark and the domain names, and any recordal thereof. Upon execution of the Assignment, the Trademark will be solely owned by Aptalis and Strakan will be bound by the terms of Section 10.7.2 herein, with respect to such ownership by Aptalis.
Assignment of Trademark. On the Effective Date, USGN shall deliver to Kidde an assignment agreement, in the form of Exhibit G, whereby USGN shall, subject to the terms of this Agreement, assign to Kidde all of its right, title and interest in the Trademark, including all goodwill associated therewith (the "Trademark Assignment Agreement"). After the Effective Date, USGN, for no further consideration, shall execute and deliver, or cause to be executed and delivered, such other instruments of conveyance, assignment, transfer and delivery, and will take such other actions, as Kidde may reasonably request in order to more effectively transfer, convey, assign and deliver to Kidde the Trademark, or to enable Kidde to exercise and enjoy all rights and benefits of USGN with respect thereto and put Kidde in actual possession and control of the Trademark. Kidde shall be responsible for any and all future expenses associated with registration and prosecution of the Trademark. During the Term of this Agreement, Kidde undertakes to use commercially reasonable efforts to protect the Trademark against infringement worldwide. During the Term of this Agreement, Kidde shall not use the Trademark except in connection with the manufacture, marketing and sale of the Products. During the Term of this Agreement, Kidde shall not assign any interest in the Trademark except to Affiliates for use solely in connection with the manufacture, marketing and sale of the Products during the Term of this Agreement. During the Term of this Agreement, Kidde may license use of the Trademark to its Affiliates, or sublicensees under Section 2.2 of this Agreement, for use in connection with the manufacture, marketing and sale of the Products.
Assignment of Trademark. Assign to Quark all of Pfizer’s right, title and interest in any trademarks used solely in connection with Licensed Products; provided that (x) the parties agree that any good faith failure by Pfizer to provide immaterial data, information, reports, records, correspondence or other materials to Quark shall not be a breach of Pfizer’s obligations under this Section 13.3, and (y) in no event shall Pfizer be required to retain any obligations or liabilities under agreements assigned to Quark pursuant to this Section 13.3 except for those arising prior to the date of assignment of such agreements. If Pfizer terminates this Agreement pursuant to Section 13.1(a), Pfizer shall, promptly after such termination, perform the activities set forth in Sections 13.3(a), (b) and (c) above. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
Assignment of Trademark. Promptly following receipt of PTC’s written notice that it intends to continue development and commercialization of Compounds and Products, Roche shall assign to PTC Roche’s and its Affiliates’ entire right, title and interest in, to and under any trademark used by any member of the Roche Group exclusively in connection with the commercialization of a Product, it being understood that such assignment shall not include the Roche name or trademark for the Roche company itself; and
Assignment of Trademark. Assignment to MethylGene all of Otsuka’s right, title and interest in any trademark used solely in connection with any Licensed Products.
